Roxadustat improves myocardial ischemia-reperfusion injury in mice by inhibiting apoptosis and inflammatory response

doi:10.11958/20240445

Abstract

Abstract:

Objective To investigate the improvement effect and related mechanism of roxadustat on myocardial ischemia-reperfusion (I/R) injury in mice. Methods Twenty four male C57BL/6N mice were randomly divided into the sham operation group, the control group and the roxadustat group, with eight mice in each group. A mouse myocardial I/R model was established. The control group was given 100 μL saline injection containing 5% dimethyl sulfoxide by gavage. The roxadustat group was given 25 mg/kg roxadustat by gavage. The left anterior descending coronary artery of mice in both groups was ligated for 40 minutes, and then reperfusion for 24 hours to establish the myocardial I/R model. In the sham operation group, only the left anterior coronary artery was pierced without ligation. The area of myocardial infarction in mice was detected by triphenyltetrazolium chloride (TTC) staining. The apoptosis of mouse cardiomyocytes was detected by TdT-mediated dUTP nick and labeling (TUNEL) staining. The expression of apoptosis-related proteins bcl-2 associated X protein (Bax), Caspase3 and inflammatory cell markers F4/80 and myeloperoxidase (MPO) were detected by immunohistochemistry staining. The damage of myocardial cells was observed by hematoxylin-eosin (HE) staining. Results The area of myocardial infarction after myocardial I/R was reduced in the roxadustat group compared to the control group and the sham operation group (P<0.05). The number of apoptotic cells was higher in the control group and the roxadustat group than that in the sham operation group, and the number of apoptotic cells was lower in the roxadustat group than that in the control group (P<0.05). The expression levels of Bax and Caspase3 proteins in myocardial tissue were higher in the control group and the roxadustat group than those in the sham operation group, while those of the roxadustat group was lower than those of the control group (P<0.05). The expression levels of F4/80 and MPO proteins in myocardial tissue were lower in the roxadustat group than those in the control group (P<0.05). In the control group, the myocardial tissue arrangement was disordered, and there was an increase in interstitial vacuoles. Compared with the control group, the myocardial cells were arranged more neatly in the roxadustat group, and the interstitial vacuoles were reduced. Conclusion Roxadustat can reduce the myocardial infarction area after I/R injury, inhibit myocardial cell apoptosis, alleviate myocardial injury, reduce infiltration of myocardial macrophages and neutrophils, and reduce inflammatory injury.

Key words: myocardial reperfusion injury, apoptosis, inflammation, Roxadustat

CLC Number:

R541

Figures/Tables 6

Fig.1 Effect of roxadustat on myocardial infarct size after I/R in mice

Fig.2 Effect of roxadustat on myocardial cell apoptosis in I/R mice (TUNEL staining， ×200)

Tab.1 Comparison of gene expression of myocardial apoptosis in myocardial I/R mice between the three groups

组别	Bax	Caspase3
假手术组	0.33±0.17	0.16±0.09
对照组	7.16±0.98^a	2.41±0.20^a
罗沙司他组	1.39±0.36^ab	0.86±0.35^ab
F	108.000^＊	71.280^＊

Fig.3 Effect of roxadustat on myocardial apoptosis gene expression after myocardial I/R in mice (immunolhistochemistry staining, ×200)

Tab.2 Comparison of myocardial macrophage infiltration after myocardial I/R between three groups of mice

组别	F4/80	MPO
假手术组	1.01±0.64	1.89±0.21
对照组	4.34±0.81^a	5.10±2.15^a
罗沙司他组	0.20±0.06^b	1.48±0.30^b
F	40.470^＊	16.370^＊

Fig.4 Effect of roxadustat on myocardial injury after myocardial I/R in mice (×200)

References 24

[1]	胡盛寿, 王增武. 《中国心血管健康与疾病报告2022》概述[J]. 中国心血管病研究, 2023, 21(7):577-600.
	HU S S, WANG Z W. Overview of report on cardiovascular health and diseases in China 2022[J]. Chinese Journal of Cardiovascular Research, 2023, 21(7):577-600. doi:10.3969/j.issn.1672-5301.2023.07.001.
[2]	TAMIS-HOLLAND J E, JNEID H, REYNOLDS H R, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease:a scientific statement from the american heart association[J]. Circulation, 2019, 139(18):e891-e908. doi:10.1161/CIR.0000000000000670.
[3]	KAHN J K. Why we get out of bed to do infarct PTCA[J]. Cathet Cardiovasc Diagn, 1996, 39(4):340. doi:10.1002/(SICI)1097-0304(199612)39:4<340::AID-CCD2>3.0.CO;2-D.
[4]	REED G W, ROSSI J E, CANNON C P. Acute myocardial infarction[M]. Treasure Island (FL): StatPearls Publishing,2023:3.
[5]	BAJAJ A, SETHI A, RATHOR P, et al. Acute complications of myocardial infarction in the current era:diagnosis and management[J]. J Investig Med, 2015, 63(7):844-855. doi:10.1097/JIM.0000000000000232.
[6]	王雅枫, 周璐, 雷少青, 等. 缺血再灌注对大鼠心肌损伤及氧化应激的影响[J]. 中华实用诊断与治疗杂志, 2018, 32(12):1157-1159.
	WANG Y F, ZHOU L, LEI S Q, et al. Influence of different reperfusion time on myocardial ischemic injury and oxidative stress in rats[J]. J Chin Pract Diagn Ther, 2018, 32(12):1157-1159.doi:10.13507/j.issn.1674-3474.2018.12.004.
[7]	朱晓宇. 罗沙司他通过调节AMPK/PGC-1α通路减少氧化应激改善肾间质纤维化的机制研究[D]. 长春: 吉林大学, 2022.
	ZHU X Y. Mechanism of Roxadustat improving renal interstitial fibrosis by reducing oxidative stress by regulating AMPK/PGC-1α pathway[D]. Changchun: Jilin University, 2022.
[8]	LI Q Y, XIONG Q W, YAO X, et al. Roxadustat:Do we know all the answers?[J]. Biomol Biomed, 2023, 23(3):354-363. doi:10.17305/bb.2022.8437.
[9]	ZHAO X N, LIU S X, WANG Z Z, et al. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria[J]. Eur J Med Res, 2023, 28(1):230. doi:10.1186/s40001-023-01179-3.
[10]	姚金东, 王妮妮, 刘亚然. 罗沙司他减轻小鼠心肌缺血再灌注损伤的作用和机制研究[J]. 中国医学创新, 2022, 19(8):15-19.
	YAO J D, WANG N N, LIU Y R. Study on the effect and mechanism of roxadustat in alleviating myocardial ischemia reperfusion injury in mice[J]. Medical Innovation of China, 2022, 19(8):15-19.doi:10.3969/j.issn.1674-4985.2022.08.004.
[11]	丁然然, 哈艳平, 王振良, 等. 低氧诱导因子-1与缺血性心肌损伤保护的研究进展[J]. 中国细胞生物学学报, 2015, 37(10):1447-1457.
	DING R R, HA Y P, WANG Z L, et al. Advances in HIF-1 and cardioprotection of ischemic myocardial injury[J]. Chinese Journal of Cell Biology, 2015, 37(10):1447-1457.doi:10.11844/cjcb.2015.10.0102.
[12]	MOKHTARI-ZAER A, MAREFATI N, ATKIN S L, et al. The protective role of curcumin in myocardial ischemia-reperfusion injury[J]. J Cell Physiol, 2018, 234(1):214-222. doi:10.1002/jcp.26848.
[13]	SUN N, MENG F, XUE N, et al. Inducible miR-145 expression by HIF-1α protects cardiomyocytes against apoptosis via regulating SGK1 in simulated myocardial infarction hypoxic microenvironment[J]. Cardiol J, 2018, 25(2):268-278. doi:10.5603/CJ.a2017.0105.
[14]	YANG Y, YU X, ZHANG Y, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury[J]. Clin Sci(Lond), 2018, 132(7):825-838. doi:10.1042/CS20171625.
[15]	CHEN N, HAO C, LIU B C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11):1011-1022. doi:10.1056/NEJMoa1901713.
[16]	LOCATELLI F, FISHBANE S, BLOCK G A, et al. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients[J]. Am J Nephrol, 2017, 45(3):187-199. doi:10.1159/000455166.
[17]	SEMENZA G L. Hypoxia-inducible factor 1 and cardiovascular disease[J]. Annu Rev Physiol, 2014,76:39-56. doi:10.1146/annurev-physiol-021113-170322.
[18]	李伟超. 应用罗沙司他治疗肾性贫血对患者微炎症因子的影响[J]. 中国实用医药, 2021, 16(2):123-125.
	LI W C. Effect of roxadustat on the microinflammatory factors in patients with renal anemia[J]. China Practical Medicine, 2021, 16(2):123-125.doi:10.14163/j.cnki.11-5547/r.2021.02.049.
[19]	HIROKO D, MASATAKA I, TOMOMI I, et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice[J]. Circ J, 2020, 84(6):1028-1033. doi:10.1253/circj.CJ-19-1039.
[20]	卜一, 张硕, 钱旭东, 等. 基于PI3K/AKT/mTOR信号通路探讨半枝莲总黄酮对脑缺血再灌注损伤大鼠神经功能和氧化应激损伤的影响[J]. 现代生物医学进展, 2022, 22(18):3440-3446.
	BU Y, ZHANG S, QIAN X D, et al. Investigate the effects of total flavonoids from scutellaria barbata on neurological function and oxidative stress injury in rats with cerebral ischemia-reperfusion injury based on PI3K/AKT/mTOR signaling pathway[J]. Progress in Modern Biomedicine, 2022, 22(18):3440-3446.doi:10.13241/j.cnki.pmb.2022.18.007.6.
[21]	KALOGERIS T, BAO Y, KORTHUIS R J. Mitochondrial reactive oxygen species:a double edged sword in ischemia/reperfusion vs preconditioning[J]. Redox Biol, 2014, 2:702-714. doi:10.1016/j.redox.2014.05.006.
[22]	WANG C, WAN H, LI M, et al. Celastrol attenuates ischemia/reperfusion-mediated memory dysfunction by downregulating AK005401/MAP3K12[J]. Phytomedicine, 2021,82:153441. doi:10.1016/j.phymed.2020.153441.
[23]	罗向红, 李丽娟, 赵婷, 等. 石斛碱对心肌缺血再灌注损伤大鼠的凋亡抑制作用[J]. 中成药, 2023, 45(6):1839-1844.
	LUO X H, LI L J, ZHAO T, et al. Inhibitory effects of dendrobine on apoptosis in rats with myocardial ischemia-reperfusion injury[J]. Chinese Traditional Patent Medicine, 2023, 45(6):1839-1844.doi:10.3969/j.issn.1001-1528.2023.06.015.
[24]	李丹, 高珊. NLRP3炎性体在心肌缺血再灌注损伤中作用的研究进展[J]. 天津医药, 2021, 49(6):656-662.
	LI D, GAO S. Research progress on the role of NLRP3 inflammasome in myocardial ischemia-reperfusion injury[J]. Tianjin Med J, 2021, 49(6):656-662.doi:10.11958/20203050.